CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $971,346 | +46.6% | 21,400 | +81.4% | 0.01% | +66.7% |
| Q2 2023 | $662,452 | +97.9% | 11,800 | +59.5% | 0.01% | +100.0% |
| Q1 2023 | $334,702 | -62.3% | 7,400 | -45.6% | 0.00% | -70.0% |
| Q3 2022 | $888,760 | -22.2% | 13,600 | -25.3% | 0.01% | -9.1% |
| Q1 2022 | $1,142,000 | -11.9% | 18,200 | +6.4% | 0.01% | +22.2% |
| Q4 2021 | $1,296,000 | -24.3% | 17,100 | +11.8% | 0.01% | -50.0% |
| Q3 2021 | $1,713,000 | +65.3% | 15,300 | +139.1% | 0.02% | +80.0% |
| Q2 2021 | $1,036,000 | +21.5% | 6,400 | -8.6% | 0.01% | +25.0% |
| Q1 2021 | $853,000 | +23.8% | 7,000 | +55.6% | 0.01% | +14.3% |
| Q4 2020 | $689,000 | -45.4% | 4,500 | -70.2% | 0.01% | -50.0% |
| Q3 2020 | $1,263,000 | +20.2% | 15,100 | +5.6% | 0.01% | +16.7% |
| Q2 2020 | $1,051,000 | +78.4% | 14,300 | +2.9% | 0.01% | +50.0% |
| Q1 2020 | $589,000 | – | 13,900 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |